BioMerieux joins research collaboration to tackle sepsis

BioMerieux has joined a new collaborative research programme called REALISM, which aims to identify and validate new biomarkers to improve care for patients at high risk of sepsis.

The company is joining forces with BIOASTER, the French accelerator of microbiology technology innovation, on this project, as well as the ESPCI college in Paris and the Hospices Civils de Lyon, plus pharmaceutical companies GlaxoSmithKline and Sanofi.

It aims to bring together medical expertise, academic research and diagnostic and pharmaceutical innovation from across the public and private sectors, with more than 50 researchers, clinicians, engineers, technicians and statisticians set to contribute.

The objective of the REALISM project is to validate new predictive tests, facilitating the diagnosis and monitoring of patients' inflammatory and immunosuppression status so that personalised diagnostic and treatment strategies can be developed.

On completion of the project at the end of 2018, the results will enable the industrial partners to develop diagnostic and therapeutic solutions to fight sepsis.

Mark Miller, chief medical officer of BioMerieux, said: "The REALISM research programme is an illustration of the long-standing commitment of BioMerieux, world leader in microbiology, in the field of sepsis."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.